biote Corp. (NASDAQ: BTMD)

Sector: Healthcare Industry: Medical Care Facilities CIK: 0001819253
Market Cap 87.65 Mn
P/B -1.20
P/E 3.04
P/S 0.45
ROIC (Qtr) 123.07
Div Yield % 0.00
Rev 1y % (Qtr) -6.67
Total Debt (Qtr) 106.41 Mn
Debt/Equity (Qtr) -1.46

About

Biote Corp., also known as BTMD, operates within the hormone optimization industry. This high-growth practice-building business specializes in providing a comprehensive platform for Biote-certified practitioners to establish and operate personalized hormone optimization programs in their practices. The company's business model is designed to enable practitioners to treat hormone imbalance through the use of bioidentical estrogen and testosterone products, as well as dietary supplements. Biote Corp.'s primary business activities revolve around the...

Read more

Price action

Investment thesis

Bull case

  • Healthy cash reserves of 28.05M provide 4.11x coverage of short-term debt 6.82M, demonstrating strong liquidity position and minimal refinancing risk.
  • Robust free cash flow of 34.41M exceeds capital expenditure of 5.58M by 6.17x, indicating strong organic growth funding capability.
  • Tangible assets of 97.42M provide exceptional 22.15x coverage of deferred revenue 4.40M, showing strong service capability backing.
  • Robust tangible asset base of 97.42M provides 119.54x coverage of working capital 815000, indicating strong operational backing.
  • Operating cash flow of 39.99M provides strong 9.09x coverage of deferred revenue 4.40M, indicating service delivery capability.

Bear case

  • Operating cash flow of 39.99M barely covers its investment activities of (5.81M), with a coverage ratio of -6.88, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Cash reserves of 28.05M provide limited coverage of acquisition spending of (231000), which is -121.42x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • The company's operating cash flow of 39.99M shows concerning coverage of stock compensation expenses of 8.61M, with a 4.65 ratio indicating potential earnings quality issues.
  • Operating cash flow of 39.99M provides minimal -23.50x coverage of tax expenses of (1.70M), suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • Free cash flow of 34.41M represents just -2.12x of debt issuance (16.25M), suggesting concerning reliance on leverage rather than internal cash generation for growth.

Peer comparison

Companies in the Medical Care Facilities
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 HCA HCA Healthcare, Inc. 114.88 Bn 18.11 1.54 46.35 Bn
2 THC Tenet Healthcare Corp 18.07 Bn 13.34 0.87 13.19 Bn
3 UHS Universal Health Services Inc 14.64 Bn 10.65 0.86 5.11 Bn
4 FMS Fresenius Medical Care AG 14.10 Bn 16.69 0.61 14.98 Bn
5 EHC Encompass Health Corp 12.55 Bn 19.95 2.17 2.66 Bn
6 ENSG Ensign Group, Inc 10.08 Bn 30.72 2.09 2.16 Bn
7 DVA Davita Inc. 8.90 Bn 11.53 0.67 12.78 Bn
8 CHE Chemed Corp 6.38 Bn 22.87 2.52 0.14 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.54 1.26
EV to Cash from Ops. EV/CFO 4.29 12.78
EV to Debt EV to Debt 1.61 12.10
EV to EBIT EV/EBIT 4.42 10.74
EV to EBITDA EV/EBITDA 4.78 16.04
EV to Free Cash Flow [EV/FCF] EV/FCF 4.98 18.02
EV to Market Cap EV to Market Cap 2.06 432.64
EV to Revenue EV/Rev 0.88 2.77
Price to Book Value [P/B] P/B -1.14 -1.92
Price to Earnings [P/E] P/E 2.89 5.13
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 0.10
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 -13.44
Dividend per Basic Share Div per Share (Qtr) 0.00 0.27
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 5.42
Interest Coverage Int. cover (Qtr) 3.31 -97.94
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 18.90 -114.65
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -26.62 65.22
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.97
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 198.63 -46.98
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -8.14 75.97
EBIT Growth (1y) % EBIT 1y % (Qtr) 99.63 -61.19
EBT Growth (1y) % EBT 1y % (Qtr) 167.79 -115.48
EPS Growth (1y) % EPS 1y % (Qtr) 175.76 -24.32
FCF Growth (1y) % FCF 1y % (Qtr) 4.44 309.51
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 4.71 17.88
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 1.76 1.04
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.04
Cash Ratio Cash Ratio (Qtr) 0.50 0.39
Current Ratio Curr Ratio (Qtr) 1.01 1.39
Debt to Equity Ratio Debt/Equity (Qtr) -1.46 -13.19
Interest Cover Ratio Int Coverage (Qtr) 3.31 -97.94
Times Interest Earned Times Interest Earned (Qtr) 3.31 -97.94
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 22.10 -95.81
EBIT Margin % EBIT Margin % (Qtr) 19.83 -94.97
EBT Margin % EBT Margin % (Qtr) 13.85 -105.60
Gross Margin % Gross Margin % (Qtr) 72.20 23.31
Net Profit Margin % Net Margin % (Qtr) 14.70 -106.14